Key result
Recent clinical trials involving SGLT-2 inhibitors and angiotensin-neprilysin inhibitors have demonstrated encouraging results in reducing heart failure hospitalizations for patients with HFpEF.
Why the study?
Despite the high prevalence and significant morbidity and mortality of HFpEF, understanding remains limited and physicians are burdened by inconclusive benefits of available treatments.
Does pharmacotherapy improve clinical outcomes and symptoms in patients with heart failure with preserved ejection fraction?
Does pharmacotherapy improve clinical outcomes and symptoms in patients with heart failure with preserved ejection fraction?
This review highlights the evolving therapeutic landscape for HFpEF, emphasizing the emerging role of SGLT-2 inhibitors and ARNIs in reducing heart failure hospitalizations despite historical challenges in finding effective treatments.
May support SGLT-2 inhibitors and ARNIs to reduce HF hospitalizations in HFpEF; leaves open need for definitive trials before practice change.
Between 2013 and 2016 there were approximately 6.2 million adults in the United States living with heart failure; nearly half had an ejection fraction that was preserved. Despite the high prevalence of heart failure with preserved ejection fraction (HFpEF), our understanding of this disease is limited and it still carries significant morbidity and mortality worldwide. At present, physicians are burdened by the inconclusive benefits of currently available treatment options. Recently the scientific community has seen an influx of new pathophysiology studies and outcome trials that have reshaped our understanding of HFpEF as a complex, multi-systemic disease. Pharmacological trials involving beta-blockers, angiotensin II receptor antagonists, aldosterone antagonists, and angiotensin-neprilysin inhibitors have demonstrated encouraging results, but have yet to reach the significance of advancements made in the treatment of heart failure with reduced ejection fraction. This review aims to summarize landmark clinical trials that have influenced current treatment guidelines, and reports on emerging evidence supporting/refuting new treatment modalities including pharmacotherapy, lifestyle modification and device therapy.
No takes yet. Share an insight, caveat, or question.
Maryniak et al. (2022) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Pharmacotherapy and device therapy was evaluated. Recent clinical trials involving SGLT-2 inhibitors and angiotensin-neprilysin inhibitors have demonstrated encouraging results in reducing heart failure hospitalizations for patients with HFpEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: